HealthEquity (HQY) Q4 2026 earnings review
Massive Operating Leverage Drives Earnings Growth Despite Muted Top-Line
HealthEquity delivered a solid Q4 to close out FY26, characterized by stable single-digit revenue growth (+7% YoY) but explosive bottom-line performance. Net Income surged 89% and Adjusted EBITDA grew 23%, showcasing tremendous operating leverage. The company successfully executed its strategy to reduce service costs and implement AI-driven efficiencies, expanding Adjusted EBITDA margin to 40%. While top-line growth is constrained by a softer labor market, capital returns remain strong with $301.7M in stock repurchased throughout the year. Initial FY27 guidance projects stable revenue growth but a deceleration in Adjusted EBITDA expansion.
🐂 Bull Case
Gross margin and Adjusted EBITDA margin expanded significantly due to cloud platform migration, AI-expedited claims, and a major reduction in fraud-related service costs. The business scales exceptionally well.
The company proactively built a cumulative $2.35 billion 5-year Treasury bond hedge at 3.92%, locking in attractive custodial yields and shielding future earnings from interest rate volatility.
🐻 Bear Case
Service revenue grew a mere 2.3% YoY in Q4. Without the tailwind of rising interest rates boosting custodial revenue, core organic account service growth looks sluggish against a soft macro backdrop.
While YoY margins are up, Adjusted EBITDA margin actually peaked in 26Q2 at 46% and has decelerated sequentially to 44% in Q3 and 40% in Q4, raising questions about the ceiling for cost-cutting.
⚖️ Verdict: 🟢
Bullish. HealthEquity is successfully transforming into a highly profitable cash machine. While macro headwinds limit spectacular top-line growth, their ability to control costs, hedge interest rate risk, and aggressively buy back stock makes the current trajectory highly attractive.
Key Themes
HSA Investments Eclipsing Cash
A structural shift is occurring in the asset base. HSA investments accelerated, growing 26% YoY to $18.5 billion, while HSA cash grew a stable but modest 3% to $18.0 billion. This marks a critical inflection point where invested assets now exceed cash balances. This shift drives higher member engagement, stickiness, and recurring fee revenue.
AI & App Mandates Drive Cost Efficiency
The massive YoY margin expansion is directly tied to the company's 'Member First' secure mobile experience strategy. By mandating App authentication and Passkey utilization, HealthEquity dramatically reduced direct fraud costs and password-reset service calls. Coupled with 'AgenTik AI' and automated claims processing, operating expenses have been structurally lowered.
Service Revenue Growth Decelerating
While total revenue grew 7%, it masked underlying weakness in core Service Revenue, which grew just 2.3% YoY to $127.1 million. This deceleration reflects a softer macroeconomic environment and sluggish job creation, highlighting the company's heavy reliance on Custodial Revenue (up 12%) and Interchange Revenue to drive the top line.
Sequential Adjusted EBITDA Margin Contraction
Despite celebrating a 40% Adjusted EBITDA margin vs 35% a year ago, the internal trajectory is reversing. Margins peaked at 46% in 26Q2, dropped to 44% in 26Q3, and further compressed to 40% in Q4. If cost-cutting tailwinds have been fully realized, future margin expansion will become significantly harder.
Other KPIs
Accelerating. Up 34% from $339.9 million in FY25. This robust cash generation more than covers the company's capital expenditures ($48.5M) and easily funded the aggressive $301.7 million share repurchase program while still allowing cash balances to grow.
Stable. Up 6% YoY. This growth outpaces total account growth (+4%), indicating increased member engagement and spending via the HealthEquity platform and stacked chip cards, though it is a deceleration from the 14% growth seen in Q1.
Stable. Account growth remains at a steady 4% YoY. HSAs specifically grew 7% to 10.6 million, offsetting slower growth in complementary Consumer-Directed Benefits (CDBs) accounts.
Guidance
Stable. The midpoint implies roughly 7.3% YoY growth, right in line with the 7% growth experienced in Q4, but slightly decelerating from the 9% full-year FY26 growth. Management expects macro headwinds to persist but views the model as resilient.
Decelerating. The midpoint of $623 million implies 10% YoY growth. While healthy, this is a sharp deceleration from the 20% growth printed in FY26, suggesting that the easiest operational efficiency and fraud-reduction wins are now largely in the rearview mirror.
Accelerating. Implies roughly 14-16% YoY growth from FY26's $4.00. The strong bottom-line translation will be aided by the ongoing share repurchase program reducing the weighted-average share count.
Key Questions
Service Revenue Strategy
Service revenue growth has slowed to low-single digits. Assuming a prolonged soft labor market, what specific pricing or bundling levers can you pull to re-accelerate core subscription growth?
Margin Ceiling
Adjusted EBITDA margin compressed sequentially from 46% in Q2 to 40% in Q4. Is 40-42% the new normalized structural run-rate, or is there a path to push margins back toward the mid-40s in FY27?
Hedge Layering Dynamics
With a cumulative $2.35B 5-year Treasury hedge locked at 3.92%, how aggressive will you be with layering additional forward contracts in FY27 if the Federal Reserve continues to cut rates?